Tag: beta-thalassemia



FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia

zynteglo approved for beta-thalassemia

bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.

Read more


Roll of Beta-Thalassemia Gene Discovered

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in beta-thalassemia,  The study, entitled “Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in B-thalassemia”  was published in the May 14, 2008 online issue of the journal Blood, the official publication of the American Society of Hematology (ASH). Splenectomy (spleen removal) […]

Read more


Secured By miniOrange